Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,ITCI,553585874,81202200,,,-68720026,,-68743782,69851164,710110,-69141054,-69141054,,,,,,23756,20046561,89187615,19336451,421028,,-68743782,-68743782,1611989381,72110788,553585874,625696662,8132,6000000,-1058587757,176118,86084,121030152,50421937,176118,24307334,601303244,433727230,15187814,7768848,15940756,48809045,7219799,48793801,1581697,-4258267,1581697,-8949736,-59325234,125581,-189455,-1525822,8046712,-15244,550881307,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,34.24,1630526403,1.0400009,33.15,34.375,32.905,366416,Intra-Cellular Therapies Inc.,NMS,PRE,-0.04360735,0,False,False,3.1325328,32.905 - 34.375,33.2,0.0,0.0,22,14,finmb_9425271,NasdaqGS,"Intra-Cellular Therapies, Inc.",USD,496014,421114,16.830002,0.96668595,17.41 - 44.8,-10.559998,-0.23571424,17.41,44.8,1620649800,1636378200,1636723800,-3.126,-1.99,2,-3.38,-10.1301775,7.545,33.05043,1.1895714,0.035992615,35.801197,-1.5611954,2780363520,-17.206032,4.538105,15,America/New_York,EDT,-14400000,1.29,,,44.8,17.41,33.05,35.8,496.01k,421.11k,81.2M,,74.16M,4.95%,91.79%,5.61M,13.49,9.23%,6.91%,5.17M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-429.85%,-28.08%,-50.88%,55.75M,0.71,951.40%,-44.86M,-239.13M,-237.37M,-3.13,,554.76M,6.82,27.28M,4.93,11.93,7.55,-238.91M,-149.43M,Value,10016,Healthcare,383,4,7,"Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.",New York,646 440 9333,NY,7,1609372800,1625097600,7,United States,http://www.intracellulartherapies.com,86400,6,430 East 29th Street,Biotechnology,Suite 900
t-1,ITCI,612149758,81202200,,,-52734943,,-52739943,52583639,-635054,-53218693,-53218693,,,,,,5000,15878329,69097022,16513383,483750,,-52739943,-52739943,1601739075,62338810,612149758,674488568,8113,4400000,-989843975,246545,86084,129979888,39701710,246545,25302041,649100443,481984786,13661992,7579393,8720957,116269249,3219132,116269249,1431658,-698762,1431658,69933955,-47766952,127008,-523008,-2897409,5746030,-15244,609398733,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,34.24,1630526403,1.0400009,33.15,34.375,32.905,366416,Intra-Cellular Therapies Inc.,NMS,PRE,-0.04360735,0,False,False,3.1325328,32.905 - 34.375,33.2,0.0,0.0,22,14,finmb_9425271,NasdaqGS,"Intra-Cellular Therapies, Inc.",USD,496014,421114,16.830002,0.96668595,17.41 - 44.8,-10.559998,-0.23571424,17.41,44.8,1620649800,1636378200,1636723800,-3.126,-1.99,2,-3.38,-10.1301775,7.545,33.05043,1.1895714,0.035992615,35.801197,-1.5611954,2780363520,-17.206032,4.538105,15,America/New_York,EDT,-14400000,1.29,,,44.8,17.41,33.05,35.8,496.01k,421.11k,81.2M,,74.16M,4.95%,91.79%,5.61M,13.49,9.23%,6.91%,5.17M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-429.85%,-28.08%,-50.88%,55.75M,0.71,951.40%,-44.86M,-239.13M,-237.37M,-3.13,,554.76M,6.82,27.28M,4.93,11.93,7.55,-238.91M,-149.43M,Value,10016,Healthcare,383,4,7,"Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.",New York,646 440 9333,NY,7,1609372800,1625097600,7,United States,http://www.intracellulartherapies.com,86400,6,430 East 29th Street,Biotechnology,Suite 900
t-2,ITCI,656860104,81202200,,,-60688946,,-60699178,58347948,-2985388,-61333336,-61333336,,,,,,10232,12454270,73787606,15439658,644390,,-60699178,-60699178,1593475506,60453570,656860104,717313674,8046,1400000,-937104032,480584,86084,60045933,36853223,480584,26323108,690904482,597402126,10764583,7056385,5501825,-176260897,-3067323,-176335663,3635334,-1554657,3635334,-240943048,-68242719,125972,-4109247,-3283979,4345693,-74766,654051259,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,34.24,1630526403,1.0400009,33.15,34.375,32.905,366416,Intra-Cellular Therapies Inc.,NMS,PRE,-0.04360735,0,False,False,3.1325328,32.905 - 34.375,33.2,0.0,0.0,22,14,finmb_9425271,NasdaqGS,"Intra-Cellular Therapies, Inc.",USD,496014,421114,16.830002,0.96668595,17.41 - 44.8,-10.559998,-0.23571424,17.41,44.8,1620649800,1636378200,1636723800,-3.126,-1.99,2,-3.38,-10.1301775,7.545,33.05043,1.1895714,0.035992615,35.801197,-1.5611954,2780363520,-17.206032,4.538105,15,America/New_York,EDT,-14400000,1.29,,,44.8,17.41,33.05,35.8,496.01k,421.11k,81.2M,,74.16M,4.95%,91.79%,5.61M,13.49,9.23%,6.91%,5.17M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-429.85%,-28.08%,-50.88%,55.75M,0.71,951.40%,-44.86M,-239.13M,-237.37M,-3.13,,554.76M,6.82,27.28M,4.93,11.93,7.55,-238.91M,-149.43M,Value,10016,Healthcare,383,4,7,"Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.",New York,646 440 9333,NY,7,1609372800,1625097600,7,United States,http://www.intracellulartherapies.com,86400,6,430 East 29th Street,Biotechnology,Suite 900
t-3,ITCI,709395535,81202200,,,-55183625,,-55183625,52473573,-3462881,-55936454,-55936454,,,,,,0,7368594,63305048,10831475,752829,,-55183625,-55183625,1585023637,61898274,709395535,771293809,8014,1400000,-876404854,768738,86084,300988981,38028717,768738,26341719,744866006,420958509,7480604,2947138,8569148,-143046851,3096161,-143216760,378494407,-12984976,378494407,171698536,-63579111,121044,-612096,-5127349,7111730,-169909,706837289,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,34.24,1630526403,1.0400009,33.15,34.375,32.905,366416,Intra-Cellular Therapies Inc.,NMS,PRE,-0.04360735,0,False,False,3.1325328,32.905 - 34.375,33.2,0.0,0.0,22,14,finmb_9425271,NasdaqGS,"Intra-Cellular Therapies, Inc.",USD,496014,421114,16.830002,0.96668595,17.41 - 44.8,-10.559998,-0.23571424,17.41,44.8,1620649800,1636378200,1636723800,-3.126,-1.99,2,-3.38,-10.1301775,7.545,33.05043,1.1895714,0.035992615,35.801197,-1.5611954,2780363520,-17.206032,4.538105,15,America/New_York,EDT,-14400000,1.29,,,44.8,17.41,33.05,35.8,496.01k,421.11k,81.2M,,74.16M,4.95%,91.79%,5.61M,13.49,9.23%,6.91%,5.17M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-429.85%,-28.08%,-50.88%,55.75M,0.71,951.40%,-44.86M,-239.13M,-237.37M,-3.13,,554.76M,6.82,27.28M,4.93,11.93,7.55,-238.91M,-149.43M,Value,10016,Healthcare,383,4,7,"Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.",New York,646 440 9333,NY,7,1609372800,1625097600,7,United States,http://www.intracellulartherapies.com,86400,6,430 East 29th Street,Biotechnology,Suite 900
